Abstract：
UNASSIGNED: To examine the demographic characteristics, findings and complication rates in patients with Behçet\'s uveitis (BU) and to investigate the effect of early biological therapy on the development of complications.
UNASSIGNED: Medical records of 94 patients with BU were retrospectively reviewed. Demographic data, ocular findings and complications at presentation, complications during follow-up, and treatments received during follow-up were analyzed. Patients who were followed for at least 24 months were divided into two groups according to the time of presentation as Group 1 (between 2009 and 2015) and Group 2 (between 2016 and 2021). Complications at the time of presentation and during follow-up, and treatments were compared.
UNASSIGNED: We enrolled 94 patients with a male-to-female ratio of 1.94 with a mean age of 30 ± 12 years. Median follow-up was 58.1(12-163) months. There were 35 patients (66 eyes) in Group 1 and 33 patients (61 eyes) in Group 2. At the time of presentation, end-stage disease, cataract, epiretinal membrane, and optic atrophy were significantly more common in Group 1 than in Group 2 (p < 0.05). A significantly higher proportion of eyes in Group 1 developed macular edema, cataract, epiretinal membrane, and macular atrophy during-follow-up (p < 0.05). Median time to initiation of biological treatment was 17.29 months in Group 1 and 3.33 months in Group 2 (p < 0.001). The overall complication rate was significantly lower in Group 2.
UNASSIGNED: Prognosis of BU is improved after the introduction of biological treatment. Early use of biological agents in BU is effective in decreasing sight-threatening ocular complications.
UNASSIGNED: Medical records of 94 patients with BU were retrospectively reviewed. Demographic data, ocular findings and complications at presentation, complications during follow-up, and treatments received during follow-up were analyzed. Patients who were followed for at least 24 months were divided into two groups according to the time of presentation as Group 1 (between 2009 and 2015) and Group 2 (between 2016 and 2021). Complications at the time of presentation and during follow-up, and treatments were compared.
UNASSIGNED: We enrolled 94 patients with a male-to-female ratio of 1.94 with a mean age of 30 ± 12 years. Median follow-up was 58.1(12-163) months. There were 35 patients (66 eyes) in Group 1 and 33 patients (61 eyes) in Group 2. At the time of presentation, end-stage disease, cataract, epiretinal membrane, and optic atrophy were significantly more common in Group 1 than in Group 2 (p < 0.05). A significantly higher proportion of eyes in Group 1 developed macular edema, cataract, epiretinal membrane, and macular atrophy during-follow-up (p < 0.05). Median time to initiation of biological treatment was 17.29 months in Group 1 and 3.33 months in Group 2 (p < 0.001). The overall complication rate was significantly lower in Group 2.
UNASSIGNED: Prognosis of BU is improved after the introduction of biological treatment. Early use of biological agents in BU is effective in decreasing sight-threatening ocular complications.
摘要：
■为了检查人口统计学特征，BU患者的发现和并发症发生率，并探讨早期生物治疗对并发症发展的影响。
■对94例BU患者的病历进行回顾性分析。人口统计数据,出现时的眼部发现和并发症，随访期间的并发症，并对随访期间接受的治疗进行分析。随访至少24个月的患者根据就诊时间分为两组，分别为第1组（2009年至2015年）和第2组（2016年至2021年）。介绍时和随访期间的并发症，并对治疗方法进行了比较。
■我们招募了94名患者，男女比例为1.94，平均年龄为30±12岁。中位随访时间为58.1(12-163)个月。第1组中有35例患者（66只眼），第2组中有33例患者（61只眼）。在介绍的时候,终末期疾病，白内障,视网膜前膜,和视神经萎缩在第1组明显多于第2组(p<0.05)。第1组出现黄斑水肿的眼睛比例明显更高，白内障,视网膜前膜,随访期间黄斑萎缩（p<0.05）。第1组开始生物治疗的中位时间为17.29个月，第2组为3.33个月（p<0.001）。第2组的总并发症发生率明显较低。
■引入生物治疗后，BU的预后得到改善。在BU中早期使用生物制剂可有效减少威胁视力的眼部并发症。
■对94例BU患者的病历进行回顾性分析。人口统计数据,出现时的眼部发现和并发症，随访期间的并发症，并对随访期间接受的治疗进行分析。随访至少24个月的患者根据就诊时间分为两组，分别为第1组（2009年至2015年）和第2组（2016年至2021年）。介绍时和随访期间的并发症，并对治疗方法进行了比较。
■我们招募了94名患者，男女比例为1.94，平均年龄为30±12岁。中位随访时间为58.1(12-163)个月。第1组中有35例患者（66只眼），第2组中有33例患者（61只眼）。在介绍的时候,终末期疾病，白内障,视网膜前膜,和视神经萎缩在第1组明显多于第2组(p<0.05)。第1组出现黄斑水肿的眼睛比例明显更高，白内障,视网膜前膜,随访期间黄斑萎缩（p<0.05）。第1组开始生物治疗的中位时间为17.29个月，第2组为3.33个月（p<0.001）。第2组的总并发症发生率明显较低。
■引入生物治疗后，BU的预后得到改善。在BU中早期使用生物制剂可有效减少威胁视力的眼部并发症。
